Apoptotic  ||| S:0 E:10 ||| FW
markers  ||| S:10 E:18 ||| FW
in  ||| S:18 E:21 ||| FW
photoinduced  ||| S:21 E:34 ||| FW
cutaneous  ||| S:34 E:44 ||| FW
carcinoma  ||| S:44 E:54 ||| FW
Cutaneous  ||| S:54 E:64 ||| FW
carcinomas  ||| S:64 E:75 ||| FW
are  ||| S:75 E:79 ||| VBP
malignant  ||| S:79 E:89 ||| JJ
lesions ||| S:89 E:96 ||| NNS
,  ||| S:96 E:98 ||| ,
which  ||| S:98 E:104 ||| WDT
most  ||| S:104 E:109 ||| JJS
commonly  ||| S:109 E:118 ||| RB
occur  ||| S:118 E:124 ||| VB
on  ||| S:124 E:127 ||| IN
photo-aggressed  ||| S:127 E:143 ||| JJ
site ||| S:143 E:147 ||| NN
.  ||| S:147 E:149 ||| .
The  ||| S:149 E:153 ||| DT
purpose  ||| S:153 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
our  ||| S:164 E:168 ||| PRP$
study  ||| S:168 E:174 ||| NN
was  ||| S:174 E:178 ||| VBD
to  ||| S:178 E:181 ||| TO
evaluate  ||| S:181 E:190 ||| VB
the  ||| S:190 E:194 ||| DT
immunohistochemical  ||| S:194 E:214 ||| JJ
expression  ||| S:214 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
three  ||| S:228 E:234 ||| CD
apoptotic  ||| S:234 E:244 ||| CD
markers  ||| S:244 E:252 ||| NNS
( ||| S:252 E:253 ||| -LRB-
p53 ||| S:253 E:256 ||| NN
,  ||| S:256 E:258 ||| ,
Bax ||| S:258 E:261 ||| NNP
,  ||| S:261 E:263 ||| ,
and  ||| S:263 E:267 ||| CC
Bcl-2 ||| S:267 E:272 ||| CD
)  ||| S:272 E:274 ||| -RRB-
in  ||| S:274 E:277 ||| IN
photoinduced  ||| S:277 E:290 ||| JJ
basal  ||| S:290 E:296 ||| NN
and  ||| S:296 E:300 ||| CC
squamous  ||| S:300 E:309 ||| JJ
cell  ||| S:309 E:314 ||| NN
carcinoma ||| S:314 E:323 ||| NN
.  ||| S:323 E:325 ||| .
The  ||| S:325 E:329 ||| DT
study  ||| S:329 E:335 ||| NN
was  ||| S:335 E:339 ||| VBD
performed  ||| S:339 E:349 ||| VBN
on  ||| S:349 E:352 ||| IN
24  ||| S:352 E:355 ||| CD
patients  ||| S:355 E:364 ||| NNS
diagnosed  ||| S:364 E:374 ||| VBN
with  ||| S:374 E:379 ||| IN
these  ||| S:379 E:385 ||| DT
forms  ||| S:385 E:391 ||| NNS
of  ||| S:391 E:394 ||| IN
cutaneous  ||| S:394 E:404 ||| NNS
carcinoma  ||| S:404 E:414 ||| VBP
localized  ||| S:414 E:424 ||| VBN
on  ||| S:424 E:427 ||| IN
photoexposed  ||| S:427 E:440 ||| JJ
regions ||| S:440 E:447 ||| NNS
:  ||| S:447 E:449 ||| :
14  ||| S:449 E:452 ||| CD
cases  ||| S:452 E:458 ||| NNS
of  ||| S:458 E:461 ||| IN
basal  ||| S:461 E:467 ||| JJ
cell  ||| S:467 E:472 ||| NN
carcinoma  ||| S:472 E:482 ||| NNS
( ||| S:482 E:483 ||| -LRB-
BCC ||| S:483 E:486 ||| NNP
)  ||| S:486 E:488 ||| -RRB-
and  ||| S:488 E:492 ||| CC
10  ||| S:492 E:495 ||| CD
cases  ||| S:495 E:501 ||| NNS
of  ||| S:501 E:504 ||| IN
squamous  ||| S:504 E:513 ||| JJ
cell  ||| S:513 E:518 ||| NN
carcinoma  ||| S:518 E:528 ||| NNS
( ||| S:528 E:529 ||| -LRB-
SCC ||| S:529 E:532 ||| NNP
) ||| S:532 E:533 ||| -RRB-
,  ||| S:533 E:535 ||| ,
classified  ||| S:535 E:546 ||| VBN
accordingly  ||| S:546 E:558 ||| RB
WHO  ||| S:558 E:562 ||| WP
2003 ||| S:562 E:566 ||| CD
.  ||| S:566 E:568 ||| .
The  ||| S:568 E:572 ||| DT
immunohistochemical  ||| S:572 E:592 ||| JJ
study  ||| S:592 E:598 ||| NN
performed  ||| S:598 E:608 ||| VBN
on  ||| S:608 E:611 ||| IN
the  ||| S:611 E:615 ||| DT
three  ||| S:615 E:621 ||| CD
proteins  ||| S:621 E:630 ||| NNS
involved  ||| S:630 E:639 ||| VBN
in  ||| S:639 E:642 ||| IN
the  ||| S:642 E:646 ||| DT
apoptotic  ||| S:646 E:656 ||| JJ
process  ||| S:656 E:664 ||| NN
revealed  ||| S:664 E:673 ||| VBD
certain  ||| S:673 E:681 ||| JJ
specific  ||| S:681 E:690 ||| JJ
features  ||| S:690 E:699 ||| NNS
in  ||| S:699 E:702 ||| IN
their  ||| S:702 E:708 ||| PRP$
manner  ||| S:708 E:715 ||| NN
of  ||| S:715 E:718 ||| IN
expression ||| S:718 E:728 ||| NN
,  ||| S:728 E:730 ||| ,
which  ||| S:730 E:736 ||| WDT
do  ||| S:736 E:739 ||| VBP
not  ||| S:739 E:743 ||| RB
correlate  ||| S:743 E:753 ||| JJ
or  ||| S:753 E:756 ||| CC
respect  ||| S:756 E:764 ||| VB
the  ||| S:764 E:768 ||| DT
critical  ||| S:768 E:777 ||| JJ
determinant  ||| S:777 E:789 ||| JJ
rule  ||| S:789 E:794 ||| NN
( ||| S:794 E:795 ||| -LRB-
Bcl-2 ||| S:795 E:800 ||| NNP
/ ||| S:800 E:801 ||| NNP
Bax ||| S:801 E:804 ||| NNP
> ||| S:804 E:805 ||| CD
1 ||| S:805 E:806 ||| CD
) ||| S:806 E:807 ||| -RRB-
.  ||| S:807 E:809 ||| .
Basal  ||| S:809 E:815 ||| JJ
cell  ||| S:815 E:820 ||| NN
carcinoma  ||| S:820 E:830 ||| NN
expresses  ||| S:830 E:840 ||| VBZ
higher  ||| S:840 E:847 ||| JJR
levels  ||| S:847 E:854 ||| NNS
of  ||| S:854 E:857 ||| IN
Bcl-2 ||| S:857 E:862 ||| NNP
,  ||| S:862 E:864 ||| ,
with  ||| S:864 E:869 ||| IN
a  ||| S:869 E:871 ||| DT
better  ||| S:871 E:878 ||| JJR
prognosis ||| S:878 E:887 ||| NN
,  ||| S:887 E:889 ||| ,
a  ||| S:889 E:891 ||| DT
less  ||| S:891 E:896 ||| RBR
aggressive  ||| S:896 E:907 ||| JJ
evolution ||| S:907 E:916 ||| NN
,  ||| S:916 E:918 ||| ,
and  ||| S:918 E:922 ||| CC
no  ||| S:922 E:925 ||| DT
metastasis ||| S:925 E:935 ||| NN
.  ||| S:935 E:937 ||| .
Squamous  ||| S:937 E:946 ||| JJ
cell  ||| S:946 E:951 ||| NN
carcinoma ||| S:951 E:960 ||| NN
,  ||| S:960 E:962 ||| ,
on  ||| S:962 E:965 ||| IN
the  ||| S:965 E:969 ||| DT
other  ||| S:969 E:975 ||| JJ
hand ||| S:975 E:979 ||| NN
,  ||| S:979 E:981 ||| ,
expresses  ||| S:981 E:991 ||| VBZ
lower  ||| S:991 E:997 ||| JJR
levels  ||| S:997 E:1004 ||| NNS
of  ||| S:1004 E:1007 ||| IN
Bcl-2 ||| S:1007 E:1012 ||| NNP
,  ||| S:1012 E:1014 ||| ,
but  ||| S:1014 E:1018 ||| CC
the  ||| S:1018 E:1022 ||| DT
clinical  ||| S:1022 E:1031 ||| JJ
outcome  ||| S:1031 E:1039 ||| NN
is  ||| S:1039 E:1042 ||| VBZ
more  ||| S:1042 E:1047 ||| RBR
aggressive ||| S:1047 E:1057 ||| JJ
,  ||| S:1057 E:1059 ||| ,
the  ||| S:1059 E:1063 ||| DT
tumor  ||| S:1063 E:1069 ||| NN
has  ||| S:1069 E:1073 ||| VBZ
a  ||| S:1073 E:1075 ||| DT
faster  ||| S:1075 E:1082 ||| JJR
evolution  ||| S:1082 E:1092 ||| NN
and  ||| S:1092 E:1096 ||| CC
may  ||| S:1096 E:1100 ||| MD
metastasize ||| S:1100 E:1111 ||| VB
.  ||| S:1111 E:1113 ||| .
P53  ||| S:1113 E:1117 ||| NN
protein  ||| S:1117 E:1125 ||| NN
respects  ||| S:1125 E:1134 ||| VBZ
the  ||| S:1134 E:1138 ||| DT
profile  ||| S:1138 E:1146 ||| NN
given  ||| S:1146 E:1152 ||| VBN
in  ||| S:1152 E:1155 ||| IN
literature  ||| S:1155 E:1166 ||| NN
data ||| S:1166 E:1170 ||| NNS
,  ||| S:1170 E:1172 ||| ,
having  ||| S:1172 E:1179 ||| VBG
a  ||| S:1179 E:1181 ||| DT
higher  ||| S:1181 E:1188 ||| JJR
score  ||| S:1188 E:1194 ||| NN
in  ||| S:1194 E:1197 ||| IN
squamous  ||| S:1197 E:1206 ||| FW
cell  ||| S:1206 E:1211 ||| FW
carcinoma  ||| S:1211 E:1221 ||| FW
versus  ||| S:1221 E:1228 ||| FW
basal  ||| S:1228 E:1234 ||| FW
cell  ||| S:1234 E:1239 ||| FW
carcinoma ||| S:1239 E:1248 ||| FW
.  ||| S:1248 E:1250 ||| .
According  ||| S:1250 E:1260 ||| VBG
to  ||| S:1260 E:1263 ||| TO
the  ||| S:1263 E:1267 ||| DT
tumor  ||| S:1267 E:1273 ||| NN
localization  ||| S:1273 E:1286 ||| NN
on  ||| S:1286 E:1289 ||| IN
photo-aggressed  ||| S:1289 E:1305 ||| JJ
sites ||| S:1305 E:1310 ||| NNS
,  ||| S:1310 E:1312 ||| ,
we  ||| S:1312 E:1315 ||| PRP
have  ||| S:1315 E:1320 ||| VBP
considered  ||| S:1320 E:1331 ||| VBN
that  ||| S:1331 E:1336 ||| IN
ultraviolet  ||| S:1336 E:1348 ||| JJ
rays  ||| S:1348 E:1353 ||| NNS
play  ||| S:1353 E:1358 ||| VBP
an  ||| S:1358 E:1361 ||| DT
important  ||| S:1361 E:1371 ||| JJ
role  ||| S:1371 E:1376 ||| NN
in  ||| S:1376 E:1379 ||| IN
initiation  ||| S:1379 E:1390 ||| NN
of  ||| S:1390 E:1393 ||| IN
carcinogenesis  ||| S:1393 E:1408 ||| NN
through  ||| S:1408 E:1416 ||| IN
still  ||| S:1416 E:1422 ||| RB
occult  ||| S:1422 E:1429 ||| JJ
mechanisms  ||| S:1429 E:1440 ||| NNS
that  ||| S:1440 E:1445 ||| WDT
may  ||| S:1445 E:1449 ||| MD
induce  ||| S:1449 E:1456 ||| VB
these  ||| S:1456 E:1462 ||| DT
particular  ||| S:1462 E:1473 ||| JJ
or  ||| S:1473 E:1476 ||| CC
rather  ||| S:1476 E:1483 ||| RB
bizarre  ||| S:1483 E:1491 ||| JJ
expressions  ||| S:1491 E:1503 ||| NNS
of  ||| S:1503 E:1506 ||| IN
apoptotic  ||| S:1506 E:1516 ||| JJ
markers ||| S:1516 E:1523 ||| NN
.  ||| S:1523 E:1525 ||| .
